Search - tctmd.com

Displaying 1 - 20 of 79

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis

News Daily News

Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis

Yael L. Maxwell

December 24, 2021

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

News Daily News

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

December 22, 2021

Correction Issued for Controversial Study Linking COVID-19 Vaccines to ACS Risk

News Daily News

Correction Issued for Controversial Study Linking COVID-19 Vaccines to ACS Risk

December 22, 2021

COVID-19: TCTMD’s Dispatch for December Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for December Week 2

December 13, 2021

The ‘Black Box’ of Asymptomatic, Stable, Ischemic CAD Treated With PCI

News Daily News

The ‘Black Box’ of Asymptomatic, Stable, Ischemic CAD Treated With PCI

December 09, 2021

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

News Daily News

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

December 03, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

News Daily News

Shock in COVID-19: Types, Triggers, and Treatments Differ, but Outlook Is Grim

November 24, 2021

COVID-19: TCTMD’s Dispatch for November Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 4

November 22, 2021

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

News Daily News

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Yael L. Maxwell

November 03, 2021

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

News Daily News

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

Yael L. Maxwell

November 02, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

News Daily News

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

October 29, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

October 05, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.